2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Germany Leader Award
Stefan Schreiber mainly investigates Genetics, Internal medicine, Immunology, Genome-wide association study and Inflammatory bowel disease. His work in Single-nucleotide polymorphism, Locus, Allele, Gene and Candidate gene is related to Genetics. His Internal medicine research incorporates themes from Gastroenterology, Placebo and Surgery.
His studies in Immunology integrate themes in fields like Intestinal mucosa and Disease. Stefan Schreiber interconnects Genetic predisposition, Allele frequency, Quantitative trait locus, Genetic architecture and Genetic association in the investigation of issues within Genome-wide association study. In his work, Colitis and Bacteria is strongly intertwined with Ulcerative colitis, which is a subfield of Inflammatory bowel disease.
Stefan Schreiber mainly focuses on Internal medicine, Genetics, Immunology, Gastroenterology and Crohn's disease. His study in the field of Ulcerative colitis and Disease is also linked to topics like In patient. His study in Genetics focuses on Single-nucleotide polymorphism, Genome-wide association study, Gene, Allele and Genetic association.
His Single-nucleotide polymorphism research is multidisciplinary, incorporating perspectives in Haplotype and Locus. His study in Inflammatory bowel disease extends to Immunology with its themes. The Gastroenterology study combines topics in areas such as Placebo and Adverse effect.
His primary scientific interests are in Internal medicine, Crohn's disease, Gastroenterology, Ulcerative colitis and Inflammatory bowel disease. As part of his studies on Internal medicine, Stefan Schreiber often connects relevant subjects like Placebo. His Crohn's disease study incorporates themes from Randomized controlled trial, Surgery, Adverse effect and Clinical trial.
His biological study spans a wide range of topics, including Moderate to severe, Antibody and Rheumatoid arthritis. Much of his study explores Ulcerative colitis relationship to Colitis. His Inflammatory bowel disease study frequently involves adjacent topics like Immunology.
His scientific interests lie mostly in Internal medicine, Crohn's disease, Gastroenterology, Ulcerative colitis and Inflammatory bowel disease. His Internal medicine course of study focuses on Placebo and Maintenance therapy. Stefan Schreiber has included themes like Surgery, Rheumatoid arthritis and Surrogate endpoint in his Crohn's disease study.
His Gastroenterology research integrates issues from Interleukin 6, Refractory and Phases of clinical research. The study incorporates disciplines such as Induction therapy, Colitis and Randomization in addition to Ulcerative colitis. His Inflammatory bowel disease study often links to related topics such as Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins;Stephan Ripke;Rinse K Weersma;Richard H Duerr.
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg;Jack Satsangi;Tariq Ahmad;Ian D. R. Arnott.
Canadian Journal of Gastroenterology & Hepatology (2005)
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
Elizabeth K. Speliotes;Elizabeth K. Speliotes;Cristen J. Willer;Sonja I. Berndt;Keri L. Monda.
Nature Genetics (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke;Dermot P B McGovern;Jeffrey C. Barrett;Kai Wang.
Nature Genetics (2010)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1
Jochen Hampe;Andre Franke;Philip Rosenstiel;Philip Rosenstiel;Andreas Till.
Nature Genetics (2007)
Hundreds of variants clustered in genomic loci and biological pathways affect human height
Hana Lango Allen;Karol Estrada;Guillaume Lettre;Sonja I. Berndt.
Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study
Benjamin F. Voight;Benjamin F. Voight;Benjamin F. Voight;Gina M. Peloso;Gina M. Peloso;Marju Orho-Melander;Ruth Frikke-Schmidt.
web science (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: